NEW YORK (GenomeWeb) – The Broad Institute confirmed that it is laying off 27 employees as the National Institutes of Health stopped funding for a program, and the institute separately decided to refocus its therapeutic development efforts.

The institute confirmed the layoffs to GenomeWeb Daily News in an email, saying the reduction in headcount comes as the NIH ended a program for service centers it had previously established to run chemical screens for labs around the country. The program was called the Molecular Libraries Probe Production Centers Network.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.